Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration

Neurology

Volumn 47, Issue 4, 1996, Pages 1032-1036

  Goto, Satoshi ^a   Matsumoto, Sadayuki ^b   Ushio, Yukitaka ^a   Hirano, Asao ^c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Kitano Hospital   (Japan)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; DEAFFERENTATION; EFFERENT NERVE; FEMALE; FUNCTIONAL ANATOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN;

EID: 0029805036     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.4.1032     Document Type: Article

References (36)

1. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
2. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-146.
3. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990;13:266-271.
4. DeLong AR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
5. Koller WC. Classification of parkinsonism. In: Koller WC, ed. Handbook of Parkinson's disease. New York: Marcel-Dekker, 1987;51-80.
6. Adams RD, Van Bogaert L, Van der Eecken. Striato-nigral degeneration. J Neuropathol Exp Neurol 1964;23:584-608.
7. Jellinger K, Danielczyk W. Striato-nigrale degeneration. Acta Neuropathol (Berl) 1968;10:242-257.
8. Takei Y, Mirra SS. Striatonigral degeneration: a form of multiple system atrophy with clinical parkinsonism. Prog Neuropathol 1973;2:217-251.
9. Adams RD, Salam-Adams M. Striatonigral degeneration. In: Vinken PJ, et al., eds. Handbook of clinical neurology. Vol 5 (49). Amsterdam: Elsevier, 1986:205-212.
10. Quinn N. Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psychiatry 1989;52:78-89.
11. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathologic study. Brain 1990;113:1823-1842.
12. Oppenheimer DR. Disease of basal ganglia, cerebellum and motor regions. In: Blackwood W, Corsellis J, eds. Greenfield's Neuropathology. 4th ed. London: Arnold, 1985:699-747.
13. Izumi K, Inoue N, Shirabe T. Failed levodopa therapy in striato-nigral degeneration. Lancet 1971;1:1355.
14. Borit A, Rubinstein LJ, Urich H. The striatonigral degenerations; putaminal pigments and nosology. Brain 1975;98:101-112.
15. Tolosa ES, Santamaria J. Parkinsonism and basal ganglia infarcts. Neurology 1984;34:1516-1518.
16. Mayo J, Arias M, Leno C, Berciano J. Vascular parkinsonism and periarteritis nodosa. Neurology 1986;36:874-875.
17. Friedman A, Kang VJ, Tatemichi TK, Burke RE. A case of parkinsonism following striatal lacunar infarction. J Neurol Neurosurg Psychiatry 1986;49:1087-1088.
18. Murrow RW, Schweiger GD, Kepes JJ, Koller WC. Parkinsonism due to a basal ganglia lacunar state: clinicopathologic correlation. Neurology 1990;40:897-990.
19. Goto S, Matsukado Y, Miyamoto E, Yamada M. Morphological characterization of the rat striatal neurons expressing calcineurin immunoreactivity. Neuroscience 1987;22:189-201.
20. Goto S, Hirano A, Rojas-Corona RR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989;25:298-304.
21. Goto S, Hirano A, Rojas-Corona RR. Calcineurin immunoreactivity in striatonigral degeneration. Acta Neuropathol (Berl) 1989;78:65-71.
22. Goto S, Hirano A. Inhomogeneity of the putaminal lesion in striatonigral degeneration. Acta Neuropathol (Berl) 1990;80: 204-207.
23. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989;26:766-770.
24. Goto S, Hirano A, Matsumoto S. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases. Ann Neurol 1990;27:520-527.
25. Szabo J. The efferent projections of the putamen in the monkey. Exp Neurol 1967;19:463-476.
26. Johnson TN, Rosvold HE. Topographic projections on the globus pallidus and the substantia nigra selectively placed lesions in the precommissural caudate nucleus and putamen in the monkey. Exp Neurol 1971;33:584-596.
27. Parent A, Bouchard C, Smith Y. The striatopallidal and striatonigral projections: two distinct fiber systems in primate. Brain Res 1984;303:385-390.
28. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington's disease. Proc Natl Acad Sci USA 1988;85:5733-5737.
29. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
30. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 1992;76:53-61.
31. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci 1992;15:285-320.
32. 11C-raclopride and positron emission tomography. Ann Neurol 1992;31:184-192.
33. Churchyard A, Donnan GA, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993;34:219-226.
34. 2 sites in Parkinson syndrome of different etiology. Brain Res 1989;483:30-38.
35. Bruyn GW, Went LN. Huntington's chorea. In: Vinken PJ, Bruyn GW, Klawans HL, eds. Handbook of clinical neurology. Vol 49. Amsterdam: Elsevier, 1986:267-313.
36. Goto S, Hirano A, Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration. Neurology 1990;40:1051-1056.